Int J Sports Med 2010; 31(1): 5-9
DOI: 10.1055/s-0029-1239500
Physiology & Biochemistry

© Georg Thieme Verlag KG Stuttgart · New York

Desmopresssin and Hemodilution: Implications in Doping

F. Sanchis-Gomar1 , V. E. Martinez-Bello1 , A. L. Nascimento1 , C. Perez-Quilis2 , J. L. Garcia-Gimenez2 , J. Viña1 , M. C. Gomez-Cabrera1
  • 1Faculty of Medicine, Department of Phisiology, University of Valencia, Valencia, Spain
  • 2CIBERER., Centre for Biomedical Research on Rare Diseases, Valencia, Spain
Further Information

Publication History

accepted after revision August 11, 2009

Publication Date:
02 November 2009 (online)

Abstract

Blood doping improves physical performance in sport. This is the reason why the antidoping authorities subject athletes to blood tests. Plasma volume expanders are prohibited agents used to reduce an artificial increase in hematological values using different illegal practices. The aim of our study was to test whether desmopressin (DDAVP)-induced hemodilution would alter the concentration of hematological parameters used to detect blood doping in sports. This was an intra-subject crossover study. Venous blood samples were obtained from eight physically active males on two occasions. On the first occasion the subjects ingested 1.5 L of mineral water and 4.3 μg/kg of DDAVP. On the second occasion the subjects ingested 1.5 L of mineral water. The samples were analyzed for hematocrit, hemoglobin, reticulocytes, OFF Hr-Score, glucose, albumin, creatinine and total proteins. After treatment with DDAVP we found a significant decrease in the hematocrit, hemoglobin and in the OFF Hr-Score values. We also found a significant decrease in glucose, albumin, creatinine and total proteins concentration; however, in this case, all the values were significantly below the physiological levels. Treatment with DDAVP has a very effective hemodilution effect. We consider that this substance should be included in the WADA's prohibited list.

References

  • 1 Astrand PO, Rodahl K. Textbook of Work Physiology. New York: McGraw-Hill 1970: 488
  • 2 Berger NJ, Campbell IT, Wilkerson DP, Jones AM. Influence of acute plasma volume expansion on VO2 kinetics, VO2 peak, and performance during high-intensity cycle exercise.  J Appl Physiol. 2006;  101 707-714
  • 3 Brien AJ, Simon TL. The effects of red blood cell infusion on 10-km race time.  JAMA. 1987;  257 2761-2765
  • 4 Cooper CE, Beneke R. Drugs and Ergogenic Aids to Improve Sport Performance. London: Portland Press 2008: 1-152
  • 5 Damsgaard R, Munch T, Morkeberg J, Mortensen SP, Gonzalez-Alonso J. Effects of blood withdrawal and reinfusion on biomarkers of erythropoiesis in humans: Implications for anti-doping strategies.  Haematologica. 2006;  91 1006-1008
  • 6 Deeg R, Kraemer W, Ziegenhorn J. Kinetic determination of serum glucose by use of the hexokinase/glucose-6-phosphate dehydrogenase method.  J Clin Chem Clin Biochem. 1980;  18 49-52
  • 7 Dimson SB. Desmopressin as a treatment for enuresis.  Lancet. 1977;  1 1260
  • 8 Donahue JL, Lowenthal DT. Nocturnal polyuria in the elderly person.  Am J Med Sci. 1997;  314 232-238
  • 9 Ekblom B, Wilson G, Astrand PO. Central circulation during exercise after venesection and reinfusion of red blood cells.  J Appl Physiol. 1976;  40 379-383
  • 10 Gomez-Cabrera MC, Domenech E, Romagnoli M, Arduini A, Borras C, Pallardo FV, Sastre J, Vina J. Oral administration of vitamin C decreases muscle mitochondrial biogenesis and hampers training-induced adaptations in endurance performance.  Am J Clin Nutr. 2008;  87 142-149
  • 11 Gore CJ, Parisotto R, Ashenden MJ, Stray-Gundersen J, Sharpe K, Hopkins W, Emslie KR, Howe C, Trout GJ, Kazlauskas R, Hahn AG. Second-generation blood tests to detect erythropoietin abuse by athletes.  Haematologica. 2003;  88 333-344
  • 12 Guddat S, Thevis M, Schanzer W. Identification and quantification of the plasma volume expander dextran in human urine by liquid chromatography-tandem mass spectrometry of enzymatically derived isomaltose.  Biomed Chromatogr. 2005;  19 743-750
  • 13 Guddat S, Thevis M, Thomas A, Schanzer W. Rapid screening of polysaccharide-based plasma volume expanders dextran and hydroxyethyl starch in human urine by liquid chromatography-tandem mass spectrometry.  Biomed Chromatogr. 2008;  22 695-701
  • 14 Gutierrez Gallego R, Segura J. Rapid screening of plasma volume expanders in urine using matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry.  Rapid Commun Mass Spectrom. 2004;  18 1324-1330
  • 15 Hill PG. The measurement of albumin in serum and plasma.  Ann Clin Biochem. 1985;  22 ((Pt 6)) 565-578
  • 16 Kim RJ, Malattia C, Allen M, Moshang  Jr  T, Maghnie M. Vasopressin and desmopressin in central diabetes insipidus: adverse effects and clinical considerations.  Pediatr Endocrinol Rev. 2004;  2 ((Suppl 1)) 115-123
  • 17 Krohn RI. The colorimetric detection and quantitation of total protein.  Curr Protoc Cell Biol. 2002;  , Appendix 3: Appendix 3H
  • 18 Levy JH. Pharmacologic methods to reduce perioperative bleeding.  Transfusion. 2008;  48 31S-38S
  • 19 Owen JA, Iggo B, Scandrett FJ, Stewart CP. The determination of creatinine in plasma or serum, and in urine; a critical examination.  Biochem J. 1954;  58 426-437
  • 20 Parisotto R, Ashenden MJ, Gore CJ, Sharpe K, Hopkins W, Hahn AG. The effect of common hematologic abnormalities on the ability of blood models to detect erythropoietin abuse by athletes.  Haematologica. 2003;  88 931-940
  • 21 Parisotto R, Gore CJ, Emslie KR, Ashenden MJ, Brugnara C, Howe C, Martin DT, Trout GJ, Hahn AG. A novel method utilising markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes.  Haematologica. 2000;  85 564-572
  • 22 Parisotto R, Wu M, Ashenden MJ, Emslie KR, Gore CJ, Howe C, Kazlauskas R, Sharpe K, Trout GJ, Xie M. Detection of recombinant human erythropoietin abuse in athletes utilizing markers of altered erythropoiesis.  Haematologica. 2001;  86 128-137
  • 23 Robinson AG. DDAVP in the treatment of central diabetes insipidus.  N Engl J Med. 1976;  294 507-511
  • 24 Sharpe K, Ashenden MJ, Schumacher YO. A third generation approach to detect erythropoietin abuse in athletes.  Haematologica. 2006;  91 356-363
  • 25 Sharpe K, Hopkins W, Emslie KR, Howe C, Trout GJ, Kazlauskas R, Ashenden MJ, Gore CJ, Parisotto R, Hahn AG. Development of reference ranges in elite athletes for markers of altered erythropoiesis.  Haematologica. 2002;  87 1248-1257
  • 26 Souillard A, Audran M, Bressolle F, Gareau R, Duvallet A, Chanal JL. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in athletes. Blood sampling and doping control.  Br J Clin Pharmacol. 1996;  42 355-364
  • 27 Thevis M, Opfermann G, Schanzer W. Detection of the plasma volume expander hydroxyethyl starch in human urine.  J Chromatogr B Biomed Sci Appl. 2000;  744 345-350
  • 28 WADA . The 2009 list of prohibited substances international standard. http://www.wada-ama.org 2009;  1-11
  • 29 Wagner PD. Determinants of maximal oxygen transport and utilization.  Annu Rev Physiol. 1996;  58 21-50

Correspondence

Dr. M. C. Gomez-Cabrera

Faculty of Medicine

Department of Physiology

University of Valencia

Avda. Blasco Ibañez, 15

46013 VALENCIA

Spain

Phone: +34/96/386 46 46

Fax: +34/96/386 46 42

Email: carmen.gomez@uv.es

    >